XML 10 R2.htm IDEA: XBRL DOCUMENT v3.25.2
Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Jun. 30, 2025
Dec. 31, 2024
Dec. 31, 2023
Current assets:      
Cash and cash equivalents [note 5] $ 51,874 $ 12,753  
Marketable securities [note 5] 3,523 21,607  
Prepaid expenses and other assets 1,506 2,107  
Total current assets 56,903 36,467  
Other assets and restricted cash [note 5] 42 39  
Right-of-use assets [note 8] 93 119  
License agreement [note 5 and note 6] 863 974  
Goodwill 1,034 1,034  
Total assets 58,935 38,633  
Current liabilities:      
Accounts payable 1,218 1,950  
Accrued liabilities other 1,219 573  
Accrued clinical liabilities 1,970 1,077  
Accrued compensation 1,563 3,027  
Contingent consideration [note 4 and note 5] 1,337 0  
Current portion of long-term obligations [note 8] 58 55  
Current portion of convertible debt [note 5 and note 6] 1,208 0  
Total current liabilities 8,573 6,682  
Non-current portion of convertible debt [note 5 and note 6] 8,657 9,837  
Contingent consideration [note 4 and note 5] 0 1,149  
Long-term obligations [note 8] 37 66  
Total liabilities 17,267 17,734  
Commitments and contingencies [note 8]  
Stockholders' equity:      
Common stock, $0.001 par value, 150,000,000 shares authorized, 49,685,072 issued and outstanding at June 30,2025 and 34,685,072 issued and outstanding at December 31, 2024 118 103  
Additional paid-in capital 272,670 226,343  
Accumulated deficit (231,123) (205,578)  
Accumulated other comprehensive income 3 31  
Total stockholders' equity 41,668 20,899 $ (1,448)
Total liabilities and stockholders' equity 58,935 38,633  
Series A Convertible Preferred Stock [Member]      
Stockholders' equity:      
Convertible preferred stock, value  
Series B Convertible Preferred Stock [Member]      
Stockholders' equity:      
Convertible preferred stock, value